China Experts Warn Against Tamiflu For Common Flu
This article was originally published in PharmAsia News
Chinese medical experts warned against giving Tamiflu to patients seeking to guard against the seasonal flu feared to plague Hong Kong. Concerned patients are asking physicians to prescribe the drug, but the experts say that would be unwise because taking Tamiflu would leave the patients more vulnerable to the H5N1 avian flu. Tamiflu already has been proved ineffective against the H1N1 common flu strain, influenza A in Hong Kong. (Click here for more
You may also be interested in...
CV Defense, the second launch in the firm’s new immune-support line (without cannabidiol), is built around palmitoylethanolamide and other nutrients and botanicals to “optimize immune response.” CV Sciences touts the immunity range as complementary to its PlusCBD brand, which is in the process of rolling out dozens of new products in updated packaging.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.
US, EU and Canadian authorities recently discussed their approaches to rolling reviews of CMC applications for coronavirus vaccines.